Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Primary Care - Continuous Glucose Monitoring

Conditions:   Type 2 Diabetes Mellitus;   Continuous Glucose Monitoring
Intervention:   Device: continuous glucose monitoring (CGM)
Sponsors:   University of Zagreb;   Association of teachers in general practice / family medicine
Recruiting - verified August 2017

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin;   Drug: Empagliflozin;   Drug: Dapagliflozin;   Drug: Dipeptidyl Peptidase-4 Inhibitor (DPP-4);   Drug: Glucagon-Like Peptide-1 Agonist (GLP-1);   Drug: Thiazolidinedione (TZD);   Drug: Sulfonylureas;   Drug: Insulin
Sponsor:   Janssen Research & Development, LLC
Active, not recruiting - verified August 2017

Exercise Using Chinese Yoga Improving Insomnia

Condition:   Exercise Promotion
Intervention:   Behavioral: Yoga
Sponsor:   Taichung Veterans General Hospital
Recruiting - verified August 2017

Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Carotid Atherosclerosis
Interventions:   Drug: Cilostazol;   Drug: Aspirin
Sponsor:   Seoul National University Bundang Hospital
Recruiting - verified August 2017

Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics

Condition:   Type2 Diabetes
Interventions:   Device: Continuous Glucose Monitor (CGM);   Device: Activity Tracker;   Behavioral: Coaching
Sponsor:   Savvysherpa, Inc.
Enrolling by invitation - verified August 2017

The Association Between Food Insecurity and Incident Type 2 Diabetes in Canada: A Population-based Cohort Study

Condition:   Type2 Diabetes
Intervention:   Other: Exposure of interest is food insecurity
Sponsors:   Christopher Tait;   Public Health Ontario
Completed - verified August 2017

Home-based Proprioceptive Neuromuscular Facilitation for Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus;   Exercise
Intervention:   Behavioral: lifestyle changes
Sponsor:   National Cheng-Kung University Hospital
Not yet recruiting - verified August 2017

Effect of Holistic Management on the Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: short-term intensive education;   Behavioral: Holistic management
Sponsor:   Cheng Qing-feng
Not yet recruiting - verified August 2017

The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D

Condition:   Glucose Metabolism Disorders
Interventions:   Drug: Placebo Oral Tablet;   Drug: Metformin;   Drug: Saline;   Drug: Exendin (9-39)
Sponsors:   University Hospital, Gentofte, Copenhagen;   University of Copenhagen
Recruiting - verified August 2017

Effects of Insulin on Hypotension and Sarcopenia

Conditions:   Diabetes;   Sarcopenia;   Hypotension, Orthostatic
Intervention:   Drug: Insulin Lispro
Sponsor:   Kenneth Madden
Not yet recruiting - verified August 2017

Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines

Condition:   Glucose Metabolism Disorders
Interventions:   Drug: Acarbose;   Drug: Placebo Oral Tablet;   Drug: Exendin (9-39);   Drug: Placebo Saline
Sponsors:   University Hospital, Gentofte, Copenhagen;   University of Copenhagen
Recruiting - verified August 2017

A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MEDI0382;   Drug: Placebo
Sponsor:   MedImmune LLC
Not yet recruiting - verified August 2017

Resistance Training in Patients With Diabetic Neuropathy

Conditions:   Diabetes Mellitus, Type 2;   Polyneuropathy Diabetes;   Diabetes Complications;   Diabetic Peripheral Neuropathy;   Muscle Weakness;   Fall Patients
Intervention:   Other: 12-week resistance training
Sponsors:   Danish Pain Research Center;   Odense University Hospital
Recruiting - verified August 2017

The Effects of Citric and Malic Acid Found in Pomegranate Juice on Glycaemic Response to White Bread.

Condition:   Hyperglycemia, Postprandial
Interventions:   Other: Control;   Other: Test
Sponsor:   University of Leeds
Active, not recruiting - verified August 2017

New IR Biomarkers (Myokines) in Colombian People

Conditions:   Insulin Resistance;   Diabetes Mellitus, Type 2
Intervention:   Other: No apply
Sponsors:   University of Los Andes, Columbia;   Departamento Administrativo de Ciencia, Tecnología e Innovación, Colciencias;   Universidad Militar Nueva Granada
Completed - verified August 2017

The "Metabolically-obese Normal-weight" Phenotype and Its Reversal by Calorie Restriction

Conditions:   Glucose Metabolism Disorders;   Obesity, Visceral;   Obesity; Endocrine;   Insulin Sensitivity/Resistance
Intervention:   Behavioral: Calorie restriction
Sponsor:   Clinical Nutrition Research Centre, Singapore
Active, not recruiting - verified August 2017

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: MEDI0382 low dose;   Drug: MEDI0382 mid dose;   Drug: MEDI0382 high dose;   Drug: Placebo;   Drug: Liraglutide
Sponsors:   AstraZeneca;   MedImmune LLC
Recruiting - verified August 2017

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LY900014;   Drug: Insulin Lispro;   Drug: Insulin Glargine;   Drug: Insulin Degludec
Sponsor:   Eli Lilly and Company
Recruiting - verified August 2017

Effectiveness of a Psychoeducational Group Intervention in Patients With Depression and Physical Comorbidity

Condition:   Depressive Disorder
Intervention:   Behavioral: Group psychoeducation
Sponsors:   Jordi Gol i Gurina Foundation;   Carlos III Health Institute
Not yet recruiting - verified August 2017

Effect of Plant and Animal Proteins on Biomarkers of Colorectal Cancer and Type 2 Diabetes in Healthy Adults (ScenoProt)

Conditions:   Colorectal Cancer;   Type2 Diabetes
Interventions:   Other: 70% animal, 30% plant proteins in diet;   Other: 50% animal, 50% plant proteins in diet;   Other: 30% animal, 70% plant proteins in diet
Sponsors:   Helsinki University;   Natural Resources Institute Finland (Luke);   Makery Ltd, Finland
Active, not recruiting - verified August 2017

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Condition:   Diabetic Peripheral Neuropathy
Interventions:   Drug: NYX-2925;   Drug: Placebo
Sponsors:   Aptinyx;   inVentiv Health Clinical
Recruiting - verified August 2017

Effects of Cinnamon Supplementation on Glucose Metabolism in Patients With Pre-diabetes

Conditions:   Dysglycemia;   Obesity
Interventions:   Dietary Supplement: Cinnamon;   Other: placebo
Sponsors:   Joslin Diabetes Center;   Kyunghee University
Recruiting - verified August 2017

Glucagon in MODY (Maturity Onset Diabetes of the Young)

Conditions:   MODY1;   MODY3
Intervention:   Other: Omission of gliclazide
Sponsors:   University of Oxford;   Oxford University Hospitals NHS Trust
Recruiting - verified August 2017

Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo
Sponsor:   AstraZeneca
Not yet recruiting - verified August 2017

Type 2 Diabetes Mellitus Patients' Characteristics and Management by General Practitioners and Endocrinologists

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2017

Breath for Better Health Study

Condition:   Type2 Diabetes
Intervention:   Dietary Supplement: Orange juice
Sponsors:   University Hospitals Coventry and Warwickshire NHS Trust;   University of Warwick
Recruiting - verified August 2017

Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Liraglutide
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2017

Inspiratory Muscle Training on Glycemic Control in Individuals With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Device: Inspiratory muscle training.;   Device: Placebo inspiratory muscle
Sponsor:   Hospital de Clinicas de Porto Alegre
Recruiting - verified August 2017

Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Insulin Degludec 100 UNT/ML [Tresiba]
Sponsors:   Merete Bechmann Christensen;   Novo Nordisk A/S
Recruiting - verified August 2017

Peanut Consumption and Cardiovascular Disease Risk in a Chinese Population

Condition:   T2D
Interventions:   Dietary Supplement: Peanut;   Dietary Supplement: Control
Sponsor:   Harvard School of Public Health
Recruiting - verified August 2017

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec/liraglutide;   Drug: Insulin degludec;   Drug: Liraglutide
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2017

A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec/liraglutide;   Drug: Insulin degludec
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2017

Empaglifozin in Early Diabetic Kidney Disease

Conditions:   Diabetic Kidney Disease;   Diabetes Mellitus Type 2
Interventions:   Drug: Empagliflozin;   Other: Placebo
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 25, 2017

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: 2.5 mg Saxagliptin tablet;   Drug: 5 mg dapagliflozin / 1000 mg metformin XR tablet;   Drug: Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR;   Drug: 5 mg saxagliptin;   Drug: 10 mg dapagliflozin / 1000 mg metformin XR tablet;   Drug: Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR
Sponsors:   AstraZeneca;   Parexel
Completed - verified August 2017

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Condition:   Diabetes Type 2 With Heart Failure
Interventions:   Drug: LIK066;   Drug: Placebo;   Drug: Empagliflozin
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified August 2017

The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.

Conditions:   Diabetes Mellitus, Type 2;   Kidney Function Tests
Intervention:   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified August 2017

Intensive Uric Acid Lowering With RDEA3170 and Febuxostat in Patients With Albuminuria

Conditions:   Hyperuricemia;   Albuminuria;   Type 2 Diabetes
Interventions:   Drug: RDEA3170 9 mg+Febuxostat 80 mg;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified August 2017

The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure

Condition:   Diabetic Foot
Interventions:   Drug: BAY1193397;   Drug: BAY1193397;   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified August 2017

Effect of SLC30A8 rs13266634 Genetic Polymorphism on Zinc Supplementation and Glycemic Control in Egyptian Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type II
Interventions:   Drug: zinc supplement plus vitamin A and E;   Drug: vitamin A and E
Sponsor:   Cairo University
Completed - verified August 2017

Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan

Condition:   Type II Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2017

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Canagliflozin;   Drug: Placebo (canagliflozin);   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2017

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2017

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec;   Drug: Insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2017

Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2017

Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: No Treatment
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2017

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide 0.5 mg;   Drug: Semaglutide 1.0 mg;   Drug: Sitagliptin placebo;   Drug: Sitagliptin;   Drug: Semaglutide placebo 0.5 mg;   Drug: Semaglutide placebo 1.0 mg
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified August 2017

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: ITCA 650 20/60 mcg/day;   Drug: Empagliflozin (oral);   Drug: Glimepiride (oral)
Sponsor:   Intarcia Therapeutics
Recruiting - verified August 2017

XIGDUO Extended Release (XR) Post Marketing Surveillance

Condition:   Adult Patients With Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2017

Study With Dapagliflozin

Condition:   Diabetes Mellitus Type 2
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2017

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified August 2017

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

Conditions:   Metabolism and Nutrition Disorder;   Obesity
Interventions:   Drug: Liraglutide 3.0 mg;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2017

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2017

Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?

Conditions:   Type 2 Diabetes;   Left Ventricular Hypertrophy
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   University of Dundee;   NHS Tayside;   AstraZeneca
Recruiting - verified August 2017

A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec/liraglutide;   Drug: Insulin degludec
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified August 2017

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified August 2017

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec/insulin aspart;   Drug: Insulin glargine;   Drug: Insulin aspart
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified August 2017

Using a Transcutaneous Electrical Auricular Stimulator to Harness the Cholinergic Anti-Inflammatory Pathway

Condition:   Healthy Volunteers
Interventions:   Device: Vagus Nerve Stimulation;   Device: Sham Vagus Nerve Stimulation
Sponsor:   Northwell Health
Recruiting - verified August 2017

Linagliptin Add-on to Insulin Background Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: linagliptin;   Drug: background therapy
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2017

Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

Condition:   Male Subjects With Type II Diabetes (T2DM)
Interventions:   Drug: AZD8601+Placebo (SAD);   Drug: AZD8601+Placebo;   Drug: Placebo+Placebo
Sponsors:   AstraZeneca;   Parexel;   Spandauer Damm 130;   14050;   Berlin, Germany
Active, not recruiting - verified August 2017

Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry

Conditions:   Diabetes Mellitus, Type 2;   Left Ventricular Systolic Dysfunction
Interventions:   Drug: Linagliptin;   Drug: Placebo
Sponsors:   Heart Care Foundation;   Fondazione dell’Associazione Medici Diabetologi
Recruiting - verified July 2016

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2017

CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Januvia Tab. 100mg;   Drug: Januvia Tab. 100mg + Duvie Tab. 0.5mg
Sponsor:   Chong Kun Dang Pharmaceutical
Completed - verified August 2017

A Study of Autologous Neo-Kidney Augment™ (NKA) in Type 2 Diabetics With Chronic Kidney Disease

Condition:   Diabetic Chronic Kidney Disease
Intervention:   Biological: Neo-Kidney Augment (NKA)
Sponsors:   inRegen;   CTI Clinical Trial and Consulting Services
Recruiting - verified August 2017

Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Non-Insulin-Dependent
Interventions:   Drug: sulforaphane;   Drug: Placebo
Sponsor:   Anders Rosengren, MD PhD
Active, not recruiting - verified August 2017

PASS to Assess Risk of Renal Injury, Hepatic Injury, Diabetic Ketoacidosis and Infections in Empagliflozin-treated Patients

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: Sulfonylurea;   Drug: DPP-4 inhibitors
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2017

Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes

Conditions:   Osteoarthritis of the Knee;   Type 2 Diabetes Mellitus
Interventions:   Drug: FX006 32 mg;   Drug: TCA IR 40 mg
Sponsor:   Flexion Therapeutics, Inc.
Completed - verified August 2017

Using Technology to Share Fitness Goals and Results to Improve Diabetes Outcomes

Condition:   Type II Diabetes Mellitus
Interventions:   Behavioral: Fitness Tracker with Group Participation;   Behavioral: Fitness Tracker
Sponsor:   Mike O'Callaghan Federal Hospital
Recruiting - verified August 2017

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine U100 (HOE901);   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified August 2017

Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention

Conditions:   Coronary Artery Disease;   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel;   Drug: Aspirin
Sponsor:   Peking Union Medical College Hospital
Recruiting - verified July 2017

A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia

Conditions:   Hypercholesterolemia;   Mixed Dyslipidemia;   Type 2 Diabetes
Interventions:   Biological: Evolocumab;   Other: Placebo to Evolocumab
Sponsor:   Amgen
Active, not recruiting - verified August 2017

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: alpha-glucosidase inhibitors;   Drug: DPP-4 inhibitors;   Drug: meglitinides;   Drug: SGLT-2 inhibitors;   Drug: sulphonylurea;   Drug: thiazolidinediones
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2017

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Conditions:   Diabetes Mellitus, Type 2;   Impaired Glucose Tolerance (IGT);   Impaired Fasting Glucose (IFG)
Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Pioglitazone;   Drug: Metformin
Sponsors:   The University of Texas Health Science Center at San Antonio;   American Diabetes Association;   AstraZeneca
Recruiting - verified August 2017

Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications

Condition:   Acute Kidney Injury
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2017

Acute Liver Injury in Patients on Dapagliflozin

Condition:   Acute Liver Injury
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2017

Complications of UTI in Patients on Dapagliflozin

Condition:   Severe Complications of Urinary Tract Infections
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2017

Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

Conditions:   Breast Cancer;   Bladder Cancer
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2017

The Role of Milk Derived Peptides on Glycaemic Control

Condition:   Insulin Resistance
Interventions:   Dietary Supplement: Water Control;   Dietary Supplement: Milk derived hydrolysate;   Dietary Supplement: Parent Protein;   Other: Lipid Load
Sponsors:   University College Dublin;   Enterprise Ireland
Completed - verified August 2017

The Effectiveness of Diabetes Self-Management Education Program Based on Behavioural Change Theory

Conditions:   Health Behavior;   Diabetes Mellitus, Type 2
Intervention:   Behavioral: Diabetes Self-Management Education
Sponsor:   University of Nottingham
Completed - verified August 2017

Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Gliclazide
Sponsor:   Seoul National University Bundang Hospital
Recruiting - verified August 2017

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin degludec;   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified August 2017

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified August 2017

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Insulin Resistance
Interventions:   Drug: Metformin;   Drug: saxagliptin;   Drug: AZD9668;   Drug: placebo
Sponsors:   Nick Giannoukakis, PhD;   National Institutes of Health (NIH);   University of Pittsburgh;   University of South Florida;   AstraZeneca
Recruiting - verified August 2017

Functional Electrical Stimulation With Rowing as Exercise After Spinal Cord Injury

Conditions:   Spinal Cord Injury;   Paraplegia;   Tetraplegia
Intervention:   Device: Functional electrical stimulation rowing (Odstock 4 channel neuromuscular stimulator with Concept 2 Rower)
Sponsor:   University of Manitoba
Enrolling by invitation - verified August 2017

Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore

Condition:   Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2017

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified August 2017

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Condition:   Type 2 Diabetes Mellitus, CKD and Albuminuria
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Dapagliflozin 10mg+Saxagliptin 2.5mg;   Drug: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
Sponsor:   AstraZeneca
Recruiting - verified August 2017

Enhance Balance and Mobility in People With Type 2 Diabetic Peripheral Neuropathy

Conditions:   Diabetes Complications;   Diabetic Neuropathies
Interventions:   Other: Muscle power;   Other: balance perturbation;   Other: aerobic exercise
Sponsors:   University of Maryland;   VA Maryland Health Care System
Recruiting - verified August 2017

Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)

Conditions:   Chronic Kidney Disease;   Type 2 Diabetes
Intervention:   Biological: Neo-Kidney Augment
Sponsors:   inRegen;   CTI Clinical Trial and Consulting Services
Completed - verified August 2017

Effect of Ramadan Fasting on Ovulation and Insuline Resistance in Patients With PCOS

Condition:   Polycystic Ovary Syndrome
Intervention:  
Sponsor:   Ain Shams University
Recruiting - verified April 2017

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Active, not recruiting - verified August 2017

The Fructose and Allulose Catalytic Effects (FACE) Trial

Condition:   Type 2 Diabetes
Interventions:   Other: Allulose;   Other: Fructose;   Other: Control
Sponsors:   University of Toronto;   Tate & Lyle
Completed - verified August 2017

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine;   Drug: insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified August 2017

Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D)

Conditions:   Diabetes;   Executive Dysfunction
Interventions:   Drug: Cholecalciferol;   Drug: Cholecalciferol
Sponsors:   Loyola University;   University of Chicago
Recruiting - verified August 2017

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GLWL-01, Part A;   Drug: Placebo, Part A;   Drug: GLWL-01, Part B;   Drug: Placebo, Part B;   Drug: GLWL-01, Part C;   Drug: Placebo, Part C
Sponsor:   GLWL Research Inc.
Terminated - verified August 2017

The Endocrine Impact of the Duodenal-jejunal Bypass Sleeve on Type 2 Diabetes - Potential Role of the Incretin Hormones

Conditions:   Type 2 Diabetes;   Obesity
Intervention:   Device: EndoBarrier Gastrointestinal Liner
Sponsors:   Filip Krag Knop;   University of Copenhagen
Completed - verified August 2017

Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy

Condition:   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Dapagliflozin;   Drug: Lobeglitazone;   Drug: Glimepirde;   Drug: Metformin
Sponsor:   Seoul National University Bundang Hospital
Recruiting - verified August 2017

Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Canagliflozin;   Drug: Liraglutide
Sponsors:   Ralph DeFronzo;   Janssen Scientific Affairs, LLC
Recruiting - verified August 2017

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin
Sponsor:   Novo Nordisk A/S
Completed - verified August 2017

Diabetes Effects on Long-Term Implant Survival and Success

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   The University of Texas Health Science Center at San Antonio;   National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified August 2017

Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management

Condition:   Type 2 Diabetes
Interventions:   Drug: Pioglitazone;   Drug: Lobeglitazone
Sponsor:   Seoul National University Bundang Hospital
Recruiting - verified August 2017

Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Drug: Insulin Glargine and Insulin Lispro
Sponsors:   GlaxoSmithKline;   PPD
Completed - verified August 2017

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Completed - verified August 2017

Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients

Condition:   Type 2 Diabetes
Intervention:   Drug: Triple combination
Sponsor:   Seoul National University Bundang Hospital
Recruiting - verified August 2017

Effect of Intranasal Insulin on LH Concentrations in Man

Condition:   Hypogonadotropic Hypogonadism
Interventions:   Drug: intranasal insulin;   Drug: placebo (intranasal saline)
Sponsor:   Texas Tech University Health Sciences Center
Recruiting - verified August 2017

ADA Linagliptin in Long Term Care

Condition:   Diabetes
Interventions:   Drug: linagliptin;   Drug: insulin glargine
Sponsors:   Emory University;   American Diabetes Association
Completed - verified August 2017

Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Placebo
Sponsors:   George Washington University;   AstraZeneca
Active, not recruiting - verified August 2017

Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in the Treatment of Type 2 Diabetes Mellitus.

Conditions:   Obesity;   Type 2 Diabetes;   Bariatric Surgery
Interventions:   Procedure: Roux-en-Y gastric bypass;   Procedure: sleeve gastrectomy
Sponsor:   Göteborg University
Recruiting - verified August 2017

Mechanisms of Diabetic Kidney Disease in American Indians

Conditions:   Nervous System;   Diabetic Kidney Disease;   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrolling by invitation - verified July 24, 2017

Study Of Diabetic Nephropathy With Atrasentan

Condition:   Diabetic Nephropathy
Interventions:   Drug: Atrasentan;   Drug: Placebo
Sponsor:   AbbVie
Recruiting - verified August 2017

Down Syndrome Metabolic Health Study

Conditions:   Down Syndrome;   Trisomy 21
Intervention:  
Sponsors:   Children's Hospital of Philadelphia;   National Institutes of Health (NIH);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2017

Korean Post-marketing Surveillance for Kombiglyze XR®

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   AstraZeneca
Completed - verified August 2017

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta tablet
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified August 2017

Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans

Condition:   Type 2 Diabetes
Intervention:   Other: Glycemic clamping
Sponsor:   Medical College of Wisconsin
Terminated - verified April 2015

Korean Post-marketing Surveillance for Onglyza®

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: No Intervention (subjects were previously treated with Onglyza®)
Sponsor:   AstraZeneca
Completed - verified August 2017

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Condition:   Children and Adolescent With Type 2 Diabetes
Interventions:   Drug: Exenatide Once Weekly;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified August 2017

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Metformin;   Drug: Sitagliptin + Metformin FDC;   Drug: Placebo to Metformin;   Drug: Placebo to Sitagliptin + Metformin FDC;   Biological: Insulin;   Biological: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified August 2017

The Effects of Glycemic Optimization Before Gastric Bypass Surgery

Condition:   Type 2 Diabetes
Intervention:   Biological: gastric bypass
Sponsor:   Imperial College London
Completed - verified August 2017

Diabetes Scorecard Educational Intervention Study

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Scorecard;   Behavioral: Control
Sponsor:   George Washington University
Completed - verified August 2017

Management of Type 2 Diabetes After Gastric Bypass Surgery

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Actrapid insulin+Gloucose;   Drug: Actrapid insulin
Sponsor:   Imperial College London
Completed - verified October 2010

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Condition:   Diabetic Nephropathies
Interventions:   Drug: PF-00489791;   Drug: Placebo
Sponsor:   Pfizer
Completed - verified August 2017

Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone

Condition:   Infant, Small for Gestational Age
Intervention:  
Sponsors:   Merck KGaA;   Merck, S.L., Spain
Active, not recruiting - verified August 2017

Type 2 Diabetes and Obesity in Mexican Pimas: Gene-Environment Interaction

Conditions:   Type 2 Diabetes Mellitus;   Obesity
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified August 7, 2017

Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

Condition:   Diabetes
Interventions:   Drug: metformin\pioglitazone\exenatide;   Drug: metformin, glyburide and glargine
Sponsors:   The University of Texas Health Science Center at San Antonio;   American Diabetes Association;   Amylin Pharmaceuticals, LLC.;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified August 2017

Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy

Conditions:   Diabetes Mellitus;   Diabetic Nephropathy
Interventions:   Drug: FG-3019;   Drug: FG-3019;   Drug: FG-3019
Sponsor:   FibroGen
Completed - verified January 2011

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: Exenatide;   Drug: Exenatide
Sponsors:   AstraZeneca;   Quintiles, Inc.
Recruiting - verified August 2017

Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients

Condition:   Diabetes Mellitus, Type II
Intervention:  
Sponsor:   Hadassah Medical Organization
Completed - verified August 2017

Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GSK716155 for injection;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified August 2017

Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: GW823093
Sponsor:   GlaxoSmithKline
Completed - verified August 2017